<?xml version="1.0" encoding="UTF-8"?><REUTERS CGISPLIT="TRAINING-SET" LEWISSPLIT="TEST" NEWID="15537" OLDID="4716" TOPICS="NO">
<DATE> 9-APR-1987 09:49:36.32</DATE>
<TOPICS/>
<PLACES><D>usa</D></PLACES>
<PEOPLE/>
<ORGS/>
<EXCHANGES/>
<COMPANIES/>
<UNKNOWN> 

   F
   f0925 reute
r f BC-BIOTHERAPEUTICS-&lt;BITX   04-09 0078</UNKNOWN>
<TEXT> 
<TITLE>BIOTHERAPEUTICS &lt;BITX&gt; REPORTS DRUG FINDINGS</TITLE>
<DATELINE>    FRANKLIN, Tenn., April 9 - </DATELINE><BODY>Biotherapeutics Inc said its
cooperative findings on interleukin-2, the anti-cancer drug,
were published today in the "New England Journal of Medicine".
    Biotherapeutics, along with the Biological Therapy
Institute and the National Cancer Institute, said the
publication focused on a reduction in toxicity through the use
of a constant infusion mode of intravenous administration
protocol.
 Reuter
 </BODY></TEXT>
</REUTERS>